GAZYVA CONCENTRATE FOR SOLUTION FOR INFUSION 1000MG/40ML [SIN14827P]

Product Info

GAZYVA CONCENTRATE FOR SOLUTION FOR INFUSION 1000MG/40ML

[SIN14827P]

2.1. THERAPEUTIC INDICATION(S)
Chronic Lymphocytic Leukaemia
Gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) see Section 3.1.2 Clinical/Efficacy Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Follicular Lymphoma
GAZYVA in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. See Section 3.1.2 Clinical/Efficacy Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Gazyva in combination with bendamustine, followed by Gazyva maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

2.2. DOSAGE AND ADMINISTRATION
General
Substitution of Gazyva with any other biological medicinal product requires the consent of the prescribing physician.
Gazyva should be administered as an intravenous infusion through a dedicated line in an environment where full resuscitation facilities are immediately available and under the close supervision of an experienced physician. Gazyva infusions should not be administered as an intravenous push or bolus. Isotonic 0.9% sodium chloride solution should be used as the infusion vehicle (see Section 4.2 Special Instructions for Use, Handling and Disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Prophylaxis and Premedication for Tumour Lysis Syndrome (TLS)
Patients with a high tumour burden and/or a high circulating lymphocyte count (> 25 x 10⁹/L) and/or renal impairment (CrCl <70 mL/min) are considered at risk of TLS and should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol) or suitable alternative such as a urate oxidase (e.g. rasburicase), prior to start of Gazyva infusion as per standard practice (see Section 2.4.1 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients should continue to receive repeated prophylaxis prior to each subsequent infusion, if deemed appropriate.

Prophylaxis and Premedication for Infusion Related Reactions (IRR)
Premedication to reduce the risk of infusion related reactions (see Section 2.4. Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) is outlined in Table 1. Corticosteroid premedication is recommended for FL patients and mandatory for CLL patients for the first infusion. Premedication for subsequent infusions and other premedication should be administered as described below.
Hypotension, as a symptom of IRR, may occur during Gazyva intravenous infusions. Therefore, withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each Gazyva infusion and for the first hour after administration (see Section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Standard Dosage
Chronic Lymphocytic Leukaemia (in combination with chlorambucil*)
Cycle 1
The recommended dosage of Gazyva is 1000 mg administered over Day 1 and Day 2 and on Day 8 and Day 15 of the first 28 day treatment cycle as shown in Table 2.
Two infusion bags should be prepared for the first dose, 100 mg for the first infusion and 900 mg for the second infusion. If the 100 mg dose is completed without modifications of the infusion rate or interruptions, the 900 mg dose can be administered on the same day (without dose delay) provided that appropriate time, conditions and medical supervision are available throughout the infusion. If there are any modifications of the infusion rate or interruptions during the first 100 mg the 900 mg infusion must be administered the following day (see Table 2).

Cycle 2–6
The recommended dosage of Gazyva is 1000mg administered on Day 1 for each 28 day treatment cycle as shown in Table 2.

*¹ See section 3.1.2 Clinical/Efficacy Studies for information on chlorambucil dose – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Delayed or missed doses (CLL)
If a planned dose of Gazyva is missed, it should be administered as soon as possible; do not wait until the next planned dose. The planned treatment interval for Gazyva should be maintained between doses.

Follicular Lymphoma
The recommended dosage of Gazyva is 1000 mg administered intravenously according to Table 3.

Previously Untreated Follicular Lymphoma
For patients with previously untreated follicular lymphoma, GAZYVA should be administered with chemotherapy as follows:

• Six 28 day cycles in combination with bendamustine² or,

• Six 21 day cycles in combination with CHOP, followed by 2 additional cycles of GAZYVA alone or,

• Eight 21 day cycles in combination with CVP.

Previously untreated patients who achieve a complete or partial response to GAZYVA plus chemotherapy should continue to receive GAZYVA (1000 mg) alone as maintenance therapy once every 2 months until disease progression or for up to 2 years.

Relapsed/Refractory Follicular Lymphoma
For patients with follicular lymphoma who have relapsed after or who are refractory to rituximab or a rituximab-containing regimen, GAZYVA should be administered in six 28 day cycles in combination with bendamustine².
Relapsed/Refractory patients who achieve complete or partial response or have stable disease should continue to receive Gazyva 1000 mg alone as maintenance therapy once every 2 months until disease progression or for up to 2 years.
GAZYVA should be administered at the standard infusion rate in Cycle 1 (see Table 3). In patients who do not experience Grade ≥3 infusion related reactions (IRRs) during Cycle 1, GAZYVA may be administered as a short (approximately 90 minutes) duration infusion (SDI) from Cycle 2 onwards (see Table 4).

² see section 3.1.2 Clinical/Efficacy Studies for information on bendamustine dose – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information

Delayed or missed doses (FL)
If a planned dose of Gazyva is missed, it should be administered as soon as possible; do not omit it or wait until the next planned dose. If toxicity occurs before Cycle 1 Day 8 or Cycle 1 Day 15, requiring delay of treatment, these doses should be given after resolution of toxicity. In such instances, all subsequent visits and the start of Cycle 2 will be shifted to accommodate for the delay in Cycle 1.
During maintenance, maintain the original dosing schedule for subsequent doses.

Dosage modifications during treatment (all indications)
No dose reductions of Gazyva are recommended.
For management of symptomatic adverse events (including IRRs), see Table 4 below and section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

2.2.1. SPECIAL DOSAGE INSTRUCTIONS
Pediatric use
The safety and efficacy of Gazyva in children below 18 years of age have not been established.

Geriatric use
No dose adjustment is required in patients ≥ 65 years of age (see section 2.5.5 Use in Special Populations, Geriatric Use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Renal impairment
No dose adjustment is required in patients with mild or moderate renal impairment. Gazyva has not been studied in patients with a CrCl ≤30mL/min (see section 2.5.5 Renal Impairment and 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Hepatic Impairment
The safety and efficacy of Gazyva in patients with hepatic impairment have not been established.

2.3. CONTRAINDICATIONS
Gazyva is contraindicated in patients with a known hypersensitivity to obinutuzumab, murine proteins or to any of the excipients.